Application | Comment | Organism |
---|---|---|
analysis | development and characterization of an in vivo applicable magnetic resonance positive contrast agent by conjugating Gd(III)-chelating agent complexes to lumazine synthase isolated from Aquifex aeolicus (AaLS). The r1 relaxivity of Gd(III)-DOTA-AaLS-R108C is 16.49 mM/s and its r1/r2 ratio is 0.52 at the magnetic field strength of 7 T. The results of 3D MR angiography demonstrate the feasibility of vasculature imaging within 2 h of intravenous injection of the agent and a significant reduction in T1 values observed in the tumor region 7 h post-injection in the SCC-7 flank tumor model. Gd(III)-DOTA-AaLS-R108C can serve as a potential theranostic nanoplatform at high magnetic field strength | Aquifex aeolicus |
Protein Variants | Comment | Organism |
---|---|---|
R108C | site-directed mutagenesis, substitution of the arginine residue at position 108 with cysteine, which is exposed on the exterior surface of the enzyme and can be used as a site for the attachment of small molecules. Construction of an in vivo applicable magnetic resonance positive contrast agent by conjugating Gd(III)-chelating agent complexes to lumazine synthase AaLS isolated from Aquifex aeolicus, measurement of T1 relaxation times of the Gd(III)-DOTA-AaLS, overview | Aquifex aeolicus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Aquifex aeolicus | O66529 | - |
- |
Synonyms | Comment | Organism |
---|---|---|
lumazine synthase | - |
Aquifex aeolicus |